Essential Financial Calendar for ALK
ALK-Abelló A/S has outlined significant events in its upcoming financial calendar, which will play a crucial role in guiding investors and stakeholders through the business's important milestones. Knowing these dates can be vital for those involved with or interested in the company’s progress and performance.
Silent Periods and Reports Overview
The financial calendar commences with the silent periods, during which ALK refrains from communicating with the public about its financial performance. The first silent period will begin on January 22, 2025, which serves as a prelude to the annual report release.
Annual Report Release
On February 19, 2025, ALK will publish its 2024 annual report. This document is essential as it provides insights into the company's performance over the past year, corporate initiatives, and forward-looking strategies. Investors often keenly anticipate such reports, as they influence investment decisions and market perceptions.
Annual General Meeting Details
ALK has scheduled its Annual General Meeting (AGM) for March 13, 2025, at 4:00 p.m. This gathering will be an opportunity for shareholders to engage with company management, ask questions, and vote on important business matters. Issues like dividends, board elects, and strategic directions are typically highlighted during these discussions.
AGM Participation and Requesting Agenda Items
Shareholders wishing to propose specific topics for discussion must submit their requests by January 29, 2025. This provision encourages active participation from shareholders, ensuring that their voices are heard during the decision-making process.
Quarterly Reports and Financial Updates
ALK's financial year will include several quarterly reports, marking essential checkpoints for performance evaluation. Following the AGM, the next silent period will begin on April 8, 2025, leading up to the release of the first-quarter report on May 6, 2025. This timely report will provide insights into ALK's operational success and early-year metrics.
Mid-Year and Further Updates
Continuing with the financial year, ALK will observe another silent period after releasing its first-quarter results. The next significant report will cover the second quarter, scheduled for August 21, 2025. In between, additional silent periods will highlight the company’s focus on maintaining consistent communications around its financial health.
Final Quarter and Year-End Reporting
The closing quarter of the financial year involves another silent period, followed by the release of the nine-month interim report on November 13, 2025. This report allows stakeholders to assess how well the company has navigated through the fiscal challenges of the year and what adjustments may be warranted moving forward.
Getting in Touch
For questions or more specific requests regarding these important dates, shareholders and interested parties are encouraged to reach out to ALK's investor relations. Per Plotnikof is the point of contact, available at +45 4574 7527 or +45 2261 2525, for inquiries related to strategic and financial matters.
About ALK
ALK is a global leader in specialty pharmaceuticals, focusing on allergy and allergic asthma cures. Their primary products include allergy immunotherapy treatments, which are essential for those struggling with allergic reactions. Headquartered in Hørsholm, Denmark, ALK employs a dedicated workforce of approximately 2,900 people and is proud to be listed on the Nasdaq Copenhagen exchange, operating under the ticker ALK B. More information about their initiatives and offerings can be found on their official website.
Frequently Asked Questions
What are the key dates to remember for ALK in 2025?
Important dates include the Annual Report release on February 19, AGM on March 13, and quarterly results on May 6, August 21, and November 13.
How can I submit a request for agenda items for the AGM?
Requests to include specific topics for discussion must be sent to the company by January 29, 2025.
Who should I contact for investor-related inquiries?
Investor inquiries can be directed to Per Plotnikof at +45 4574 7527 or +45 2261 2525.
What is the primary focus of ALK as a company?
ALK focuses on developing and marketing allergy immunotherapy treatments for allergy sufferers and aspiring healthcare professionals.
How does ALK’s financial calendar impact investors?
Understanding these key dates allows investors to make informed decisions and assess the company’s performance effectively throughout the year.